论文部分内容阅读
目的 :探讨脑转移瘤放疗疗效及预后因素。方法 :从 1997年 6月～ 2 0 0 0年 10月对 36例脑转移瘤进行放射治疗 ,采用 6MV X线 ,两侧平行相对野作全脑照射 ,1 8～ 3Gy/次 ,30～ 40Gy后缩野针对转移灶加量 16～ 2 0Gy。结果 :总的中位生存期为 5 3个月 ,6个月生存率为 44 4% (16 / 36 ) ,1年生存率为 13 9% (5 / 36 )。按RTOG脑转移瘤RPA预后分级 ,Ⅰ、Ⅱ和Ⅲ级中位生存期分别为 10个月、5个月和 2 8个月。Ⅰ级中位生存期明显长于Ⅱ级 (P <0 0 5 )和Ⅲ级 (P <0 0 1)。结论 :KPS、年龄、原发灶控制情况及颅外有无转移灶是脑转移患者的预后因素 ,RPA预后分级对脑转移瘤临床治疗有指导价值
Objective: To investigate the efficacy and prognostic factors of radiotherapy for brain metastases. Methods: From June 1997 to October 2000, 36 cases of brain metastases were treated with radiotherapy. The 6MV X-ray was used. The whole brain was irradiated with parallel wild relatives of both sides, 18 ~ 3Gy / time, 30 ~ 40Gy After the reduction of metastasis for the amount of 16 ~ 20Gy. RESULTS: The median overall survival was 53 months. The 6-month survival rate was 44.4% (16/36) and the 1-year survival rate was 13.9% (5/36). According to the prognosis classification of RPA in brain metastases of RTOG, the median survival time of stage Ⅰ, Ⅱ and Ⅲ were 10 months, 5 months and 28 months respectively. Grade I median survival was significantly longer than grade II (P <0.05) and grade III (P <0.01). Conclusion: KPS, age, control of primary tumor and extracranial metastases are prognostic factors in patients with brain metastases. The classification of RPA prognosis has guiding value for the clinical treatment of brain metastases